Last edition
News about "Dr. Howard L. Weiner"
Tiziana Doses Last Patient in Phase 2 Trial of Foralumab
Tiziana has dosed the last patient in its phase 2 trial of intranasal foralumab for mild Alzheimer’s, evaluating monotherapy and combinations with lecanemab or donanemab.
Dr. Howard L. Weiner | 19/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members